BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34763611)

  • 1. The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.
    Opolka-Hoffmann E; Jordan G; Otteneder M; Kieferle R; Lechmann M; Winter G; Staack RF
    MAbs; 2021; 13(1):1995929. PubMed ID: 34763611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies.
    Hoffmann E; Jordan G; Lauer M; Ringler P; Kusznir EA; Rufer AC; Huber S; Jochner A; Winter G; Staack RF
    Pharm Res; 2019 Jun; 36(9):129. PubMed ID: 31254106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution.
    Opolka-Hoffmann E; Edelmann MR; Otteneder MB; Hauri S; Jordan G; Schrag P; Lechmann M; Winter G; Staack RF
    AAPS J; 2024 Mar; 26(2):33. PubMed ID: 38478197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
    Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
    J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
    Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
    MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method combining blue native polyacrylamide gel electrophoresis with liquid chromatography tandem-mass spectrometry to detect circulating immune complexes between therapeutic monoclonal antibodies and anti-drug antibodies in animals.
    Kobayashi K; Tahara H; Kagawa Y
    J Pharm Biomed Anal; 2020 Jul; 186():113329. PubMed ID: 32371323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.
    van Schie KA; Kruithof S; Ooijevaar-de Heer P; Derksen NIL; van de Bovenkamp FS; Saris A; Vidarsson G; Bentlage AEH; Jiskoot W; Romeijn S; Koning RI; Bos E; Stork EM; Koeleman CAM; Wuhrer M; Wolbink G; Rispens T
    Ann Rheum Dis; 2018 Oct; 77(10):1471-1479. PubMed ID: 29945923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species.
    Glover ZK; Wecksler A; Aryal B; Mehta S; Pegues M; Chan W; Lehtimaki M; Luo A; Sreedhara A; Rao VA
    MAbs; 2022; 14(1):2122957. PubMed ID: 36151884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies.
    Hock BD; McKenzie JL; Strother M; Goddard L; Butt L; Currie MJ
    Cancer Immunol Immunother; 2020 Dec; 69(12):2453-2464. PubMed ID: 32556495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
    Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
    MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies.
    Mortensen DL; Prabhu S; Stefanich EG; Kadkhodayan-Fischer S; Gelzleichter TR; Baker D; Jiang J; Wallace K; Iyer S; Fielder PJ; Putnam WS
    MAbs; 2012; 4(6):724-31. PubMed ID: 23778267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.